The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 05, 2024

Filed:

Dec. 28, 2021
Applicant:

Infirst Healthcare Limited, London, GB;

Inventors:

Robin M. Bannister, Saffron Walden, GB;

John Brew, St. Albans, GB;

Richard R. Reiley, III, London, GB;

Wilson Caparros Wanderley, Aylesbury, GB;

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/00 (2006.01); A61K 9/08 (2006.01); A61K 31/121 (2006.01); A61K 31/137 (2006.01); A61K 31/167 (2006.01); A61K 31/192 (2006.01); A61K 31/196 (2006.01); A61K 31/222 (2006.01); A61K 31/357 (2006.01); A61K 31/366 (2006.01); A61K 31/4178 (2006.01); A61K 31/4184 (2006.01); A61K 31/522 (2006.01); A61K 31/60 (2006.01); A61K 31/616 (2006.01); A61K 47/10 (2017.01); A61K 47/14 (2017.01); A61K 47/22 (2006.01); A61K 47/44 (2017.01);
U.S. Cl.
CPC ...
A61K 47/14 (2013.01); A61K 31/121 (2013.01); A61K 31/137 (2013.01); A61K 31/167 (2013.01); A61K 31/192 (2013.01); A61K 31/196 (2013.01); A61K 31/222 (2013.01); A61K 31/357 (2013.01); A61K 31/366 (2013.01); A61K 31/4178 (2013.01); A61K 31/4184 (2013.01); A61K 31/522 (2013.01); A61K 31/60 (2013.01); A61K 31/616 (2013.01); A61K 47/10 (2013.01); A61K 47/22 (2013.01); A61K 9/08 (2013.01); A61K 47/44 (2013.01); Y02A 50/30 (2018.01);
Abstract

The present specification discloses solid solution pharmaceutical compositions comprising therapeutic compound comprising a phytocannabinoid in an amount of less than about 55%, one or more pharmaceutically-acceptable hard fats in an amount of at least 25% by weight of the pharmaceutical composition, and one or more pharmaceutically-acceptable liquid lipids in an amount of 1% to 50% by weight of the pharmaceutical composition, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.


Find Patent Forward Citations

Loading…